Inclusion Criteria:  Acute GvHD Patients  Patients who develop acute SR-GvHD after first HSCT and there is a minimum of 6 months follow up data in the database Patients who initiate treatment with ECP or Ruxolitinib within 60 days of onset of SR aGvHD Grade: II-IV only at time of treatment initiation Patients who are ≥ 18 years at time of treatment initiation  Chronic GvHD Patients  Patients who develop chronic SR-GvHD after first HSCT and there is with a minimum of 1 year follow up data in the database Patients who initiate treatment with ECP or Ruxolitinib or Ibrutinib within I year of the onset of SR-cGvHD Severity: moderate to severe only at time of treatment initiation Patients who are ≥ 18 years at time of treatment initiation  Exclusion Criteria:  Acute GvHD  Patients on a clinical trial for GvHD for an interventional drug to treat GvHD in the retrospective period Patient is pregnant or breastfeeding Grade I at time of SR GvHD treatment initiation Patients who receive ECP or new treatment as prophylaxis Patients initiating ECP or new treatment later than 60 days from onset on SR-aGvHD Patients < 18 years at time of treatment initiation  Chronic GvHD  Patients on a clinical trial for an interventional drug to treat GvHD in the retrospective period Patient is pregnant or breastfeeding Chronic GvHD : Severity mild at time of SR GvHD treatment initiation Patients who receive ECP or new treatment as prophylaxis Patients initiating ECP or new treatment after 1 year onset of SR-cGvHD Patients < 18 years at time of treatment initiation